Beigene
Beigene, a leading biotechnology company headquartered in China (CN), is at the forefront of developing innovative therapies for cancer and other serious diseases. Founded in 2010, Beigene has rapidly expanded its operations across major regions, including North America, Europe, and Asia, establishing a strong global presence in the biopharmaceutical industry. The company is renowned for its robust pipeline of targeted therapies and immuno-oncology products, with a focus on precision medicine. Notable achievements include the successful development of its flagship drug, Brukinsa, which has gained recognition for its efficacy in treating various forms of blood cancer. Beigene's commitment to research and development, coupled with strategic partnerships, positions it as a key player in the competitive landscape of oncology therapeutics.
DitchCarbon Score
How does Beigene's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Beigene's score of 33 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Beigene's reported carbon emissions
In 2023, Beigene reported total carbon emissions of approximately 555,892,000 kg CO2e. This figure includes 2,463,000 kg CO2e from Scope 1 emissions, primarily from stationary and mobile combustion, and 76,485,000 kg CO2e from Scope 2 emissions, which are associated with purchased electricity. The company also disclosed significant Scope 3 emissions, totalling about 476,965,000 kg CO2e, with the largest contributions from purchased goods and services, capital goods, and employee commuting. Over the years, Beigene has shown fluctuations in its emissions. For instance, in 2021, total emissions were approximately 324,097,000 kg CO2e, while in 2022, they increased to about 274,416,000 kg CO2e. The company has not set specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges, indicating a potential area for future commitment. Beigene's emissions data reflects its operational scale and the challenges faced in reducing carbon footprints in the biopharmaceutical industry. The company continues to monitor and report its emissions, aligning with industry standards for transparency and accountability in climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 535,000 | 000,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 5,929,000 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Beigene is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
